Oral Tranexamic Acid After Total Knee Arthroplasty

This is a prospective, double-blind, randomized controlled trial evaluating the efficacy of oral tranexamic acid (TXA) in total knee arthroplasty (TKA). The study will assess pain, function, and range of motion (ROM) over a 2-year period, with key evaluations at 6 weeks and 90 days postoperatively. Hypothesis: Patients receiving 1.95g oral TXA for 3 or 7 days post-op will show improved pain, function, and ROM at 6 weeks and 90 days, with similar blood loss and transfusion rates as the control group.

NCT Number	NCT06894719
Lead Sponsor	Rush University Medical Center
Conditions	Total Knee Arthroplasty
Enrollment	351 participants
Start Date	2026-09-01
Primary Completion	2026-12-01 (estimated)
Study Completion	2027-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-23